PMID- 35620481
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2296-889X (Print)
IS  - 2296-889X (Electronic)
IS  - 2296-889X (Linking)
VI  - 9
DP  - 2022
TI  - Identification of TRP-Related Subtypes, Development of a Prognostic Model, and 
      Characterization of Tumor Microenvironment Infiltration in Lung Adenocarcinoma.
PG  - 861380
LID - 10.3389/fmolb.2022.861380 [doi]
LID - 861380
AB  - The TRP (transient receptor potential) superfamily, as cation channels, is a 
      critical chemosensor for potentially harmful irritants. Their activation is 
      closely related not only to tumor progression and prognosis but also to tumor 
      therapy response. Nevertheless, the TRP-related immune gene (TRIG) expression of 
      the tumor microenvironment (TME) and the associations with prognosis remain 
      unclear. First, we represented the transcriptional and genetic variations in 
      TRIGs in 535 lung adenocarcinoma (LUAD) samples as well as their expression 
      patterns. LUAD samples were divided into two distinct subtypes based on the TRIG 
      variations. Significant differences had been found in prognosis, clinical 
      features, and TME cell-infiltration features between the two subtypes of 
      patients. Second, we framed a TRIG score for predicting overall survival (OS) and 
      validated the predictive capability of the TRIG score in LUAD patients. 
      Accordingly, to enhance the clinical applicability of TRIG score, we developed a 
      considerable nomogram. A low TRIG score, characterized by increased immunity 
      activation, indicated favorable advantages of OS compared with a high TRIG score. 
      Furthermore, the TRIG score was found to have a significant connection with the 
      TME cell-infiltration and immune checkpoint expressions. Our analysis of TRIGs in 
      LUAD showed their potential roles in prognosis, clinical features, and 
      tumor-immune microenvironments. These results may advance our knowledge of TRP 
      genes in LUAD and show a new light on prognosis estimation and the improvement of 
      immunotherapy strategies.
CI  - Copyright (c) 2022 Sun, Wang, Li and Wu.
FAU - Sun, Sibo
AU  - Sun S
AD  - Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Wang, Yu
AU  - Wang Y
AD  - Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Li, Min
AU  - Li M
AD  - Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Wu, Jianqing
AU  - Wu J
AD  - Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20220510
PL  - Switzerland
TA  - Front Mol Biosci
JT  - Frontiers in molecular biosciences
JID - 101653173
PMC - PMC9127446
OTO - NOTNLM
OT  - TRP superfamily
OT  - immunotherapy
OT  - lung adenocarcinoma
OT  - overall survival
OT  - tumor-immune microenvironment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/05/28 06:00
MHDA- 2022/05/28 06:01
PMCR- 2022/01/01
CRDT- 2022/05/27 02:29
PHST- 2022/01/24 00:00 [received]
PHST- 2022/03/30 00:00 [accepted]
PHST- 2022/05/27 02:29 [entrez]
PHST- 2022/05/28 06:00 [pubmed]
PHST- 2022/05/28 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 861380 [pii]
AID - 10.3389/fmolb.2022.861380 [doi]
PST - epublish
SO  - Front Mol Biosci. 2022 May 10;9:861380. doi: 10.3389/fmolb.2022.861380. 
      eCollection 2022.